Daily Archives: January 26, 2022 | LinksMedicus Free Medical News & Perspectives

RCT: Heterologous (Pfizer, J&J, or AstraZeneca) vs. homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil.

26 Jan, 2022 | 02:30h | UTC

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study – The Lancet

Commentaries:

Boosting immunity after CoronaVac – The Lancet

Covid-19: CoronaVac immunity is strongest after boosting with a different vaccine – The BMJ

Commentary on Twitter

Heterologous boosting after 2 doses of #CoronaVac COVID-19 vaccine results in more robust immune responses than homologous boosting, study suggests. https://t.co/845JFnn3t7 pic.twitter.com/ibT3b5rs2K

— The Lancet (@TheLancet) January 23, 2022

As Pfizer and BioNTech begin a clinical trial of Omicron-based vaccine, the timeline to authorization is unclear.

26 Jan, 2022 | 02:20h | UTC

As Pfizer and BioNTech begin clinical trial of Omicron-based vaccine, timeline to authorization is unclear – STAT

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

26 Jan, 2022 | 02:23h | UTC

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 – JAMA

Commentary: COVID 19: Risk of Myocarditis Highest Following Second Vaccine Dose Among Adolescent and Young Adult Males – MedicalResearch.com

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

Cohort study: Among patients who survived ICU treatment for COVID-19, 75% still reported physical, mental, or cognitive symptoms after 1 year.

26 Jan, 2022 | 02:28h | UTC

Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19 – JAMA

Commentaries:

75% of COVID ICU survivors have physical symptoms 1 year on – CIDRAP

Majority of COVID-19 survivors experience health problems one-year post ICU admission – News Medical

Deltacron: the story of the variant that wasn’t.

26 Jan, 2022 | 02:19h | UTC

Deltacron: the story of the variant that wasn’t – Nature

USPSTF Recommendation Statement: Still not enough evidence to recommend atrial fibrillation screening.

26 Jan, 2022 | 02:08h | UTC

Final Recommendation Statement: Screening for Atrial Fibrillation – U.S. Preventive Services Task Force

Author Interview: USPSTF Recommendation: Screening for Atrial Fibrillation – JAMA

Editorials:

Screening for Atrial Fibrillation—More Data Still Needed – JAMA

Screening for Atrial Fibrillation—New Devices, Same Challenges – JAMA Internal Medicine

Updated USPSTF Guidelines for Screening for Atrial Fibrillation: Same as It Ever Was? – JAMA Cardiology

Screening for Atrial Fibrillation—Refining the Target – JAMA Network Open

JAMA Patient Page: Screening for Atrial Fibrillation

Commentary: USPSTF: Data Around Screening for AF in Asymptomatic Adults Still Lacking – TCTMD

Opinion: Preventing SARS-CoV-2 transmission in health care settings in the context of the Omicron variant.

26 Jan, 2022 | 02:14h | UTC

Preventing SARS-CoV-2 Transmission in Health Care Settings in the Context of the Omicron Variant – JAMA

Commentary on Twitter

Our new piece in @JAMA_current

Transmission of #SARSCoV2 in healthcare settings is a serious concern

We outline three ways hospitals can better prepare for surges— mandating boosters, increasing frequency of testing, & upgrading to N95 maskshttps://t.co/2xRKdKPlhO pic.twitter.com/y0L4UzUNSo

— Abraar Karan (@AbraarKaran) January 24, 2022

Guidelines on the management of Type B aortic dissection.

26 Jan, 2022 | 02:06h | UTC

The Society of Thoracic Surgeons/American Association for Thoracic Surgery Clinical Practice Guidelines on the Management of Type B Aortic Dissection – Annals of Thoracic Surgery

News Release: New practice guideline addresses diagnosis, treatment of type B aortic dissection – The Society of Thoracic Surgeons

[Preprint] High prevalence of olfactory disorders 18 months after contracting COVID-19.

26 Jan, 2022 | 02:11h | UTC

High prevalence of olfactory disorders 18 months after contracting COVID-19 – medRxiv

Commentaries:

Half of first-wave Covid cases may have lasting harm to sense of smell – The Guardian

Prevalence of olfactory dysfunction 18 months after SARS-CoV-2 infection – News Medical

RCT: Acetazolamide prevents adverse altitude effects in COPD and healthy adults.

26 Jan, 2022 | 01:53h | UTC

Acetazolamide to Prevent Adverse Altitude Effects in COPD and Healthy Adults – NEJM Evidence

Mass casualty medicine and anesthesia special issue: science and clinical practice.

26 Jan, 2022 | 02:04h | UTC

Editorials:

Mass casualty medicine: time for a 21st century refresh

Exercising for mass casualty preparedness

Massive transfusion and severe blood shortages: establishing and implementing predictors of futility

Transfusion support during mass casualty events

Embracing uncertainty in mass casualty incidents

Pre-hospital critical care at major incidents

Provision of pre-hospital medical care for terrorist attacks

Higher pre-hospital anaesthesia case volumes result in lower mortality rates: implications for mass casualty care

Improving mass casualty planning in low resource settings: Médecins Sans Frontières and International Committee of the Red Cross perspective

Global lessons learned from COVID-19 mass casualty incidents

Reimagining health preparedness in the aftermath of COVID-19

Preparing for mass casualty events despite COVID-19

Paediatric Anaesthesia:

Paediatric patients in mass casualty incidents: a comprehensive review and call to action

Adaptations to practice and resilience in a paediatric major trauma centre during a mass casualty incident

Pre-hospital Care:

Injury scoring systems for blast injuries: a narrative review

Association between case volume and mortality in pre-hospital anaesthesia management: a retrospective observational cohort

Establishing quality indicators for pre-hospital advanced airway management: a modified nominal group technique consensus process

Pre-hospital continuous positive airway pressure after blast lung injury and hypovolaemic shock: a modelling study

Preparedness:

Review of the requirements for effective mass casualty preparedness for trauma systems. A disaster waiting to happen?

Learning from terrorist mass casualty incidents: a global survey

Refining mass casualty plans with simulation-based iterative learning

Specific Incidents:

Mass casualty, intentional vehicular trauma and anaesthesia

Chemical, biological, radiological, and nuclear mass casualty medicine: a review of lessons from the Salisbury and Amesbury Novichok nerve agent incidents

Correspondence:

Pre-hospital oral transmucosal fentanyl citrate for trauma analgesia: preliminary experience and implications for civilian mass casualty response

Implications for trauma system development in a low- and middle-income country: the Sri Lanka 2019 Easter Sunday terrorist attack

Development and evaluation of a mass casualty medicine simulation method using figurines

Influx! A game-based learning tool for in-hospital interprofessional disaster preparedness and response

RCT: Electronic directly observed therapy is noninferior to in-person observed therapy for ensuring adherence to tuberculosis treatment.

26 Jan, 2022 | 01:58h | UTC

In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence: A Randomized Noninferiority Trial – JAMA Network Open

Commentary on Twitter

In this 2-year study, data showed that electronic directly observed therapy (eDOT) was as effective as traditional in-person DOT for ensuring high adherence to treatment of tuberculosis disease. @CDC_TB @nycHealthy @ColumbiaMed https://t.co/yTrU1JRuwn pic.twitter.com/QXthE4d266

— JAMA Network Open (@JAMANetworkOpen) January 20, 2022

Perspective: The value of patient-reported outcomes in early-phase clinical trials.

26 Jan, 2022 | 01:47h | UTC

The value of patient-reported outcomes in early-phase clinical trials – Nature Medicine (if the link is paywalled, try this one)

Commentary on Twitter

A @NatureMedicine Comment article argues that patient-reported outcomes, if used correctly, can provide preliminary evidence of efficacy and tolerability from a patient perspective, as well as supporting regulatory review. https://t.co/4ztwW76P2T pic.twitter.com/6sFRvswgJ2

— Nature Portfolio (@NaturePortfolio) January 24, 2022

A review of high impact journals found that misinterpretation of non-statistically significant results from randomized trials was common.

26 Jan, 2022 | 01:50h | UTC

A review of high impact journals found that misinterpretation of non-statistically significant results from randomised trials was common – Journal of Clinical Epidemiology

Opinion | “The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice”.

26 Jan, 2022 | 01:52h | UTC

The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice – European Journal of Human Genetics

Commentary: ‘Unproven and unethical’: experts warn against genetic embryo tests – The Guardian

A registry study with 1,581 cases of Stenotrophomonas maltophilia blood and/or lower respiratory infections suggest Levofloxacin is a reasonable alternative to standard therapy with Trimethoprim-sulfamethoxazole.

26 Jan, 2022 | 01:40h | UTC

Trimethoprim-Sulfamethoxazole versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 U.S. Hospitals – Open Forum Infectious Diseases

Commentary on Twitter

A new study in OFID suggests that mortality outcomes are similar comparing levofloxacin and TMP/SMX treatment of S. maltophilia lower respiratory tract and bloodstream infections.

?:https://t.co/80QDy3DTU9 #IDSAJournals @PaulSaxMD @DrJLi @Keith_S_Kaye @SameerKadri12 pic.twitter.com/TNxQpfT97n

— IDSA (@IDSAInfo) January 23, 2022